Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00288015 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab in Treating Patients With Angiosarcoma
A Phase 2 study of Sarcoma, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 5
- Study locations
NCT00288015: Completed Phase 2 study of Sarcoma, sponsored by Northwestern University.
NCT00288015 is a Phase 2 study of Sarcoma that has completed, run by Northwestern University. The registered enrollment target is 32 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00288015, a Phase 2 study of Sarcoma, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 5
- Study locations
Study Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with angiosarcoma.
Primary Outcome
During treatment, tumor assessment was done by MRI scan after the second cycle of study treatment, after the forth cycle of study treatment, and then every 3 cycles of treatment thereafter. After Study drug completion, tumor assessment by MRI was done every 3 to 4 months (for up to 2 years after the last bevacizumab dosage). Responses were categorized according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.0. Progressive Disease (PD) was defined as having at least
Conditions Studied
Interventions
- BIOLOGICAL Bevacizumab
Study Locations (5)
California
- Rebecca and John Moores UCSD Cancer Center - La Jolla
Illinois
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University - Chicago
Minnesota
- Mayo Clinic Cancer Center - Rochester
Pennsylvania
- Fox Chase Cancer Center CCOP Research Base - Philadelphia
Texas
- M. D. Anderson Cancer Center at University of Texas - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2005-10 |
| Est. Completion | 2016-11-10 |
| Phase | Phase 2 |
What the finished NCT00288015 record still lists
NCT00288015 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Bevacizumab is the first listed.
NCT00288015 lists 5 locations in 5 states (California, Illinois, Minnesota).
Frequently Asked Questions
What is clinical trial NCT00288015 about?
NCT00288015 is a clinical study titled "Bevacizumab in Treating Patients With Angiosarcoma". RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by bloc...
What is the current status of trial NCT00288015?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2005-10. Estimated completion is 2016-11-10.
What conditions does trial NCT00288015 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT00288015?
The interventions under investigation include: Bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00288015?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00288015 being conducted?
This trial has 5 study locations across California, Illinois, Minnesota, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00288015's enrollment target sits among peer trials
32 83rd of 122 higher than 39 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
RECRUITING · Phase 2
-
Fluorescent Intra-operative Tumor Margin Examination
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia